« Return to News | Clinical Intelligence

Eisai's eribulin gets EU approval for breast cancer

Tuesday, March 29, 2011 12:44 PM

Regulators in Europe have approved Eisai’s marine-derived breast cancer drug Halaven.

The Japanese drugmaker received approval from the European Commission for Halaven (eribulin) for the treatment of patients with locally advanced breast cancer who have progressed after at least two chemotherapy regimens. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

The approval is based on the phase III EMBRACE study which demonstrated that Halaven superiority when compared with treatment of physician's choice (TPC). That data demonstrated median overall survival of 13.2 versus 10.5 months.

Eisai plans to launch Halaven first in the U.K., followed by Germany and the Nordic countries. It was approved in the U.S. in November 2010 and in Singapore this year, while other applications are currently under review in Japan, Switzerland and Canada.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.